[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:synovial-sarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":105,"states":106},"Synovial Sarcoma",15,14,[8,16,23,30,36,42,48,55,62,68,74,80,86,92,98],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07261657","N-803 in Patients With Progressive Synovial Sarcoma and Myxoid\u002FRound Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy",[12],"Early Phase 1","RECRUITING","2026-08-26T02:19:07.104270Z","2026-07-05T05:32:16.673151Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06946225","ACTengine® IMA203 Combined With mRNA-4203",[20],"Phase 1","2026-08-26T02:15:29.632183Z","2026-05-05T02:43:26.949927Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT03016819","Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)",[27],"Phase 3","2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.260312Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06644755","First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:27.064259Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06083883","Phase I\u002FIb Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1",[20],"2026-08-26T02:18:26.129155Z","2026-04-29T02:57:57.066842Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05711615","Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma",[20],"2026-08-26T02:19:30.857183Z","2026-07-05T05:32:16.811405Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06571734","XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma",[52],"Phase 2","2026-08-26T02:17:14.343713Z","2026-07-05T05:32:16.766529Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":60,"content_modified":61},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[59],"Phase 1\u002FPhase 2","2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT04995003","HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",[20],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.987147Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[52],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.251035Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05227326","AOH1996 for the Treatment of Refractory Solid Tumors",[20],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:26.920202Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT05642455","SPEARHEAD-3 Pediatric Study",[59],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.852369Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT06235125","Safety and Feasibility of Intraoperative Visualization With Cytalux in Children",[20],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.069602Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT05910307","Synovial Sarcoma Registry \u002F Biospecimen Repository",[],"2026-08-26T02:18:17.007929Z","2026-05-13T02:55:06.392533Z",{"nct_id":99,"title":100,"phases":101,"status":102,"updated_at":103,"content_modified":104},"NCT06748872","EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And\u002For Synovial Sarcoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.536530Z",[],[107,111,114,117,121,124,127,131,134],{"state":108,"count":109,"slug":110},"California",5,"california",{"state":112,"count":109,"slug":113},"Illinois","illinois",{"state":115,"count":109,"slug":116},"Texas","texas",{"state":118,"count":119,"slug":120},"Massachusetts",4,"massachusetts",{"state":122,"count":119,"slug":123},"New York","new-york",{"state":125,"count":119,"slug":126},"Pennsylvania","pennsylvania",{"state":128,"count":129,"slug":130},"Florida",3,"florida",{"state":132,"count":129,"slug":133},"Missouri","missouri",{"state":135,"count":129,"slug":136},"Washington","washington"]